Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 3
1985 3
1986 3
1987 2
1988 5
1990 1
1991 2
1992 1
1993 3
1994 1
1995 2
1996 3
1997 3
1998 1
1999 1
2000 1
2001 1
2002 1
2004 1
2006 1
2007 1
2008 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Alterations in lymphocyte subpopulations in copper-deficient mice.
Lukasewycz OA, Prohaska JR, Meyer SG, Schmidtke JR, Hatfield SM, Marder P. Lukasewycz OA, et al. Among authors: marder p. Infect Immun. 1985 Jun;48(3):644-7. doi: 10.1128/iai.48.3.644-647.1985. Infect Immun. 1985. PMID: 3997239 Free PMC article.
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, Chaudhary A, Fife K, Battiato L, Sweeney C, Jordan C, Burgess M, Slapak CA. Sandler A, et al. Among authors: marder p. Clin Cancer Res. 2004 May 15;10(10):3265-72. doi: 10.1158/1078-0432.CCR-03-0644. Clin Cancer Res. 2004. PMID: 15161679 Clinical Trial.
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA. Rubin EH, et al. Among authors: marder p. Clin Cancer Res. 2002 Dec;8(12):3710-7. Clin Cancer Res. 2002. PMID: 12473580 Clinical Trial.
43 results